I-9922 Ingenol 3-Hexanoate, 99%

Synonyms : [Ingenol B]

  • Size
  • US $
  • £
  • ¥
  • 1 mg
  • 57
  • 47
  • 41
  • 6,300
  • Add to Cart
  • Out of stock
  • 5 mg
  • 176
  • 147
  • 129
  • 19,500
  • Add to Cart
  • Out of stock
  • 10 mg
  • 289
  • 241
  • 212
  • 32,000
  • Add to Cart
  • Out of stock
  • 25 mg
  • 499
  • 417
  • 367
  • 55,300
  • Add to Cart
  • Out of stock
  • 50 mg
  • 792
  • 662
  • 582
  • 87,800
  • Add to Cart
  • Out of stock
  • 100 mg
  • 1,385
  • 1,157
  • 1,019
  • 153,600
  • Add to Cart
  • Out of stock
  • 200 mg
  • 2,175
  • 1,818
  • 1,600
  • 241,200
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 446.58
  • C26H38O6
  • [83036-61-7]

Certificate of Analysis

  • Ingenol-3-hexanoate was more potent in reactivating latent HIV than other known activators such as SAHA, ingenol 3,20-dibenzoate, TNF-α, PMA and HMBA. Ingenol-3-hexanoate alone was able to reactivate virus transcription in primary HIV-infected latent cells up to 12 fold, and up to 25 fold in combination with SAHA. Pandeló José D., et al. "Reactivation of latent HIV-1 by new semi-synthetic ingenol esters." Virology 462-463: 328-339 (2014).
  • Synthetic ingenol derivatives referred to as ingenol A, B, and C activated the HIV-LTR in reporter cell lines and latent virus in human PBMCs at concentrations as low as 10 nM. They were also able to inhibit the replication of HIV-1 subtype B and C in MT-4 cells and human PBMCs with EC50 values of 0.02 and 0.09 µM respectively. Abreu C.M., et al. "Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR." PLoS One 9: e97257 (2014).
  • Highly active antiretroviral therapy (HAART) effectively suppresses HIV viral replication; however, it fails to eradicate latent viral reservoirs. Ingenol-3-hexanoate is a potent activator of latent HIV reservoirs, possibly via protein kinase C[delta]-Nf-[kappa]B signaling. Jiang G., et al. "Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling." AIDS 28: 1555-1566 (2014).
  • Related CAS numbers: 59086-90-7 for ingenol-3,20-dibenzoate.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
557